FDA’s approval of Sandoz Inc./Momenta Pharmaceuticals Inc. generic glatiramer acetate (Glatopa) reiterates the agency’s determination to find a way to approve copies of complex, difficult-to-copy drugs.
That’s the foundational message from the April 16 approval, and from the very substantive, simultaneous rejection